X0407 4 2023-06-12 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001354434 Renaud Ronald C JR C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 1 1 0 0 President & CEO 0 Stock Option (Right to Buy) 32.72 2023-06-12 4 A 0 215749 0.00 A 2033-06-12 Common Stock 215749 215749 D Restricted Stock Units 2023-06-12 4 A 0 160452 0.00 A Common Stock 160452 160452 D Performance-based Restricted Stock Units 2023-06-12 4 A 0 160371 0.00 A Common Stock 160371 160371 D 25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date. The shares reported in this transaction represent the target number of performance-based RSUs ("PSUs") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return ("TSR") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics. /s/ Mark Bodenrader, as Attorney-in-Fact 2023-06-14